GLENN JOHN

SEC source: 0001253497-26-000005 · wk-form4_1782221342.xml · derivative · entry 3

GLENN JOHN · CIK 0001253497 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,796 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on June 30, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on June 30, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001253497-26-000005 · wk-form4_1782221342.xml · nonDerivative · entry 2

GLENN JOHN · CIK 0001253497 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,937

SEC source: 0001253497-26-000005 · wk-form4_1782221342.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,256

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

SEC source: 0001253497-26-000002 · form4-03052026_070321.xml · derivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,907

Underlying: Common Stock · 8,907 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 7, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

F2 · derivative.expiration_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 7, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001253497-25-000015 · form4-12122025_051211.xml · derivative · entry 5

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,624

Underlying: Common Stock · 1,812 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

F3 · derivative.expiration_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001253497-25-000015 · form4-12122025_051211.xml · nonDerivative · entry 4

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,460

SEC source: 0001253497-25-000015 · form4-12122025_051211.xml · nonDerivative · entry 3

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,174

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: Restricted stock units convert into common stock on a one-for-one basis.

F2 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001253497-25-000015 · form4-12122025_051211.xml · nonDerivative · entry 2

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,362

SEC source: 0001253497-25-000015 · form4-12122025_051211.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,894

F1 · price: This transaction was executed in multiple trades at prices ranging from $97.00 to $97.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001253497-25-000010 · form4-12102025_051204.xml · derivative · entry 6

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,008 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: If the relative measure at December 7, 2025 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100%and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares.

F4 · derivative.exercise_date: On December 7, 2022, the reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of specified relative ranking of total shareholder return over a three-year period from December 8, 2022 through December 7, 2025.

F4 · derivative.expiration_date: On December 7, 2022, the reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of specified relative ranking of total shareholder return over a three-year period from December 8, 2022 through December 7, 2025.

SEC source: 0001253497-25-000010 · form4-12102025_051204.xml · derivative · entry 5

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,504 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The reporting person received restricted stock units ("RSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in full on the third anniversary of the grant date, December 7, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

F3 · derivative.expiration_date: The reporting person received restricted stock units ("RSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in full on the third anniversary of the grant date, December 7, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001253497-25-000010 · form4-12102025_051204.xml · nonDerivative · entry 4

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,362

SEC source: 0001253497-25-000010 · form4-12102025_051204.xml · nonDerivative · entry 3

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,629

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: If the relative measure at December 7, 2025 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100%and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares.

F2 · price: If the relative measure at December 7, 2025 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100%and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares.

SEC source: 0001253497-25-000010 · form4-12102025_051204.xml · nonDerivative · entry 2

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,621

SEC source: 0001253497-25-000010 · form4-12102025_051204.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,004

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Restricted stock units convert into common stock on a one-for-one basis.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001253497-25-000008 · form4-11122025_041101.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500

F1 · price: This transaction was executed in multiple trades at prices ranging from $84.25 to $85.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-25-018013 · form4-06232025_080616.xml · derivative · entry 3

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,796

Underlying: Common Stock · 5,796 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents shares of common stock that the Reporting Peron received upon the vesting of restricted stock units ("RSUs") on a one-for-one basis.

F2 · derivative.exercise_date: On June 20, 2022, the Reporting Person received RSUs under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the Reporting Person will receive a number of shares of common stock equal to the number of RSUs that have vested.

F2 · derivative.expiration_date: On June 20, 2022, the Reporting Person received RSUs under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the Reporting Person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001415889-25-018013 · form4-06232025_080616.xml · nonDerivative · entry 2

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,151

SEC source: 0001415889-25-018013 · form4-06232025_080616.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,563

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of common stock that the Reporting Peron received upon the vesting of restricted stock units ("RSUs") on a one-for-one basis.

F1 · price: Represents shares of common stock that the Reporting Peron received upon the vesting of restricted stock units ("RSUs") on a one-for-one basis.

SEC source: 0001415889-24-029268 · form4-12132024_041201.xml · derivative · entry 2

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,119

Underlying: Common Stock · 5,435 shares

Expires not disclosed

F3 · derivative.exercise_price: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. PRSUs convert into common stock on a one-for-one basis. The PRSUs vest over a three-year performance period from December 12, 2024 through December 11, 2027 on the Company's total stockholder return compared to the NASDAQ US Small Cap Medical Equipment index.

F3 · derivative.exercise_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. PRSUs convert into common stock on a one-for-one basis. The PRSUs vest over a three-year performance period from December 12, 2024 through December 11, 2027 on the Company's total stockholder return compared to the NASDAQ US Small Cap Medical Equipment index.

F3 · derivative.expiration_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. PRSUs convert into common stock on a one-for-one basis. The PRSUs vest over a three-year performance period from December 12, 2024 through December 11, 2027 on the Company's total stockholder return compared to the NASDAQ US Small Cap Medical Equipment index.

SEC source: 0001415889-24-029268 · form4-12132024_041201.xml · derivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,508

Underlying: Common Stock · 5,436 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

F2 · derivative.expiration_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001415889-24-028036 · form4-12022024_091202.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,383

F1 · price: This transaction was executed in multiple trades at prices ranging from $54.00 to $54.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-25-010210 · form4-04042025_040401.xml · derivative · entry 3

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,592

Underlying: Common Stock · 5,796 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents shares of common stock that the Reporting Peron received upon the vesting of restricted stock units ("RSUs") on a one-for-one basis.

F3 · derivative.exercise_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

F3 · derivative.expiration_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001415889-25-010210 · form4-04042025_040401.xml · nonDerivative · entry 2

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,767

F2 · shares: The transaction was inadvertently reported late. The aggregate amount of securities beneficially owned includes the delinquent transaction plus all transactions reported in Form 4's filed after the date of the delinquent transaction.

SEC source: 0001415889-25-010210 · form4-04042025_040401.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,179

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of common stock that the Reporting Peron received upon the vesting of restricted stock units ("RSUs") on a one-for-one basis.

F2 · shares: The transaction was inadvertently reported late. The aggregate amount of securities beneficially owned includes the delinquent transaction plus all transactions reported in Form 4's filed after the date of the delinquent transaction.

F1 · price: Represents shares of common stock that the Reporting Peron received upon the vesting of restricted stock units ("RSUs") on a one-for-one basis.

SEC source: 0001415889-25-010289 · form4a-04072025_040401.xml · derivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,592

Underlying: Common Stock · 5,796 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: When vested, restricted stock units ("RSUs") are convertible into common stock on a one-for-one basis.

F2 · shares: On April 4, 2025, the Reporting Person filed a Form 4, which inadvertently stated in Column 5 of Table II that 5,796 RSUs were acquired instead of disposed. This inadvertent misstatement has been corrected in this amended filing to note that 5,796 RSUs were disposed.

F3 · derivative.exercise_date: On June 20, 2022, the Reporting Person received RSUs under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the Reporting Person will receive a number of shares of common stock equal to the number of RSUs that have vested.

F3 · derivative.expiration_date: On June 20, 2022, the Reporting Person received RSUs under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the Reporting Person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001415889-23-016253 · form4-12112023_061212.xml · derivative · entry 2

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,684

Underlying: Common Stock · 7,180 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of specified relative ranking of total shareholder return over a three-year period from December 8, 2023 through December 7, 2026.

F4 · derivative.exercise_date: If the relative measure at December 7, 2026 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100%and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares.

F5 · derivative.exercise_date: Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested.

F3 · derivative.expiration_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of specified relative ranking of total shareholder return over a three-year period from December 8, 2023 through December 7, 2026.

F4 · derivative.expiration_date: If the relative measure at December 7, 2026 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100%and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares.

F5 · derivative.expiration_date: Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested.

SEC source: 0001415889-23-016253 · form4-12112023_061212.xml · derivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,072

Underlying: Common Stock · 7,180 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The reporting person received restricted stock units ("RSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in full on the third anniversary of the grant date, December 7, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

F2 · derivative.expiration_date: The reporting person received restricted stock units ("RSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in full on the third anniversary of the grant date, December 7, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001415889-23-010149 · form4-06222023_040601.xml · derivative · entry 3

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,388

Underlying: Common Stock · 5,795 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On June 20, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On June 20, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-23-010149 · form4-06222023_040601.xml · nonDerivative · entry 2

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,883

SEC source: 0001415889-23-010149 · form4-06222023_040601.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-22-000666 · form4.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

F1 · price: This transaction was executed in multiple trades at prices ranging from $28.61 to $28.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000898432-22-000660 · form4.xml · derivative · entry 2

GLENN JOHN · CIK 0001253497 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,504

Underlying: Common Stock · 10,504 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F3 · derivative.exercise_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of a specified relative ranking of total stockholder return over a three-year period from December 8, 2022 through December 7, 2025.

F4 · derivative.exercise_date: If the relative measure at December 7, 2025 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100% and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares.

F5 · derivative.exercise_date: Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested.

F3 · derivative.expiration_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of a specified relative ranking of total stockholder return over a three-year period from December 8, 2022 through December 7, 2025.

F4 · derivative.expiration_date: If the relative measure at December 7, 2025 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100% and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares.

F5 · derivative.expiration_date: Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested.

SEC source: 0000898432-22-000660 · form4.xml · derivative · entry 1

GLENN JOHN · CIK 0001253497 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,687

Underlying: Common Stock · 10,504 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in full on the third anniversary of the grant date, December 7, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in full on the third anniversary of the grant date, December 7, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-22-000409 · form4.xml · derivative · entry 1

GLENN JOHN · CIK 0001253497 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23.183

Underlying: Common Stock · 23.183 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-22-000462 · form4.xml · derivative · entry 1

GLENN JOHN · CIK 0001253497 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,183

Underlying: Common Stock · 23,183 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F3 · derivative.underlying_shares: This Form 4/A is being filed solely to correct administrative errors in (i) the number of shares of Common Stock underlying Restricted Stock Units shown as acquired and beneficially held by the reporting person and (ii) the vesting commencement date of such Restricted Stock Units in his Form 4 filed on June 23, 2022 (the "Original Form 4"). All other information set forth in the Original Form 4 remains correct.

SEC source: 0001209191-22-021330 · doc4.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,130

F1 · shares: Represents shares sold by the Reporting Person on March 22, 2022 to cover tax withholding obligations incurred upon the vesting and settlement of the first installment of restricted stock awards reported by the Reporting Person in Form 4s filed with the Commission on February 22, 2022 and March 5, 2021.

F2 · price: The sale price represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $2.88 to $2.81, inclusive. The Company can provide the full information regarding the number of shares sold at each separate price upon further request.

SEC source: 0001209191-22-011950 · doc4.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,592

F1 · shares: Shares acquired pursuant to a restricted stock units award granted on March 3, 2021 that had both performance-based and time-based vesting conditions. The performance-based vesting conditions have been satisfied, and now the award is subject only to time-based vesting conditions. The award vests in three equal annual installments beginning on March 3, 2022.

SEC source: 0001209191-21-018246 · doc4.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,996

F1 · security: Represents restricted stock units ("RSUs").

F2 · date: The grant of RSUs was approved by the compensation committee of the board of directors on March 3, 2021.

F3 · shares: The grant consists of RSUs that vest annually over three years.

SEC source: 0001209191-20-022637 · doc4.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,981

F1 · date: The grant of the RSUs was approved by the compensation committee of the company's board of directors on November 6, 2019 contingent upon (a) approval by the company's stockholders at the next occurring special or annual meeting of the stockholders (to increase the number of shares reserved for issuance under the company's Amended and Restated 2014 Equity Incentive Plan to accommodate the grants of the RSUs), which approval was obtained at a special meeting of the stockholders on March 12, 2020, and (b) the company filing a registration statement on Form S-8 with the Securities and Exchange Commission (the "SEC") to register the offer and sale of the shares underlying the RSUs, which registration statement was filed with the SEC on April 1, 2020.

F2 · price: The grant consists of restricted stock units ("RSUs") that vest as to one quarter (1/4th) of the total number listed above on November 15, 2020, and as to an additional one quarter (1/4th) of the total number of RSUs listed above on November 15 of each following year.

F3 · balance_after: After taking into account the 1-for-15 reverse stock split effective March 24, 2020.

SEC source: 0001209191-19-055863 · doc4.xml · derivative · entry 1

GLENN JOHN · CIK 0001253497 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 640,000

Underlying: Common Stock · 240,000 shares

Expires 2029-11-06

F1 · derivative.exercise_date: The option becomes exercisable as to 1/48th of the total number of shares on December 6, 2019 and thereafter as to 1/48th of the total number of shares on the same day of each month.

SEC source: 0001209191-19-037946 · doc4.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,708

F1 · shares: The shares were sold by the filer to satisfy the tax obligations of the filer in connection with a grant of common stock on April 24, 2019 in lieu of cash payment of bonus for services performed in 2018.

SEC source: 0001209191-19-026248 · doc4.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · shares: The shares were awarded in lieu of cash payment of bonus for services performed as an executive officer in 2018.

SEC source: 0001209191-18-049259 · doc4.xml · derivative · entry 1

GLENN JOHN · CIK 0001253497 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2028-08-31

F1 · derivative.exercise_date: The option becomes exercisable as to 25% of the total number of shares on August 31, 2019 and thereafter vests in equal monthly installments for 36 months.